{
  "pmcid": "4029101",
  "sha256": "313244cfbbdc4f239822be1cfaa28f0a47ccab2d44e120fc583c9267c28605f4",
  "timestamp_utc": "2025-11-09T23:52:00.969981+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.417311022311022,
    "reading_ease": 28.138673826173857,
    "word_count": 273
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sequential Interventions for Posttransplant Lymphoproliferative Disease in Adult Solid Organ Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Participants": {
        "score": 2,
        "evidence": "adult solid organ transplant recipients with biopsy-proven PTLD"
      },
      "Intervention": {
        "score": 2,
        "evidence": "RI involved a 50% reduction in cyclosporine or tacrolimus for 2 weeks, with a further 50% reduction for 1 week if complete remission (CR) was not achieved."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial assessed a sequential treatment algorithm for posttransplant lymphoproliferative disease (PTLD) in adult solid organ transplant recipients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was CR, measured over the treatment course."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Sixteen eligible patients were analysed."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Sixteen eligible patients were analysed."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "RI resulted in 1 partial response (12.5%) and no CR. Progressive disease occurred in 50% and rejection in 38%."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not detailed."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}